Recent Updates
Recently added Catalysts
NMRA Negative Sentiment Score: 25/100

Neumora Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 7, 2025 Deadline to file Lead Plaintiff Motion.

Key Takeaway: Neumora Therapeutics, Inc. is facing a class action lawsuit after allegations of misleading statements regarding its Phase Two trials for Navacaprant, its lead candidate for treating Major Depressive Disorder. Investors are advised to contact the Portnoy Law Firm to discuss their options for recovering losses, with a deadline set for April 7, 2025, to file a lead plaintiff motion. The lawsuit claims Neumora modified trial criteria and analysis methods, raising questions about the integrity and adequacy of data reported in clinical studies. The firm provides complimentary case evaluations to affected investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors are urged to file a lead plaintiff motion due to alleged misleading statements by Neumora.
  • The complaint claims Neumora altered trial inclusion criteria to manipulate results.
  • Concerns about insufficient data in Phase Two trials, affecting the validity of study outcomes.
  • Accusations indicate potential corporate wrongdoing that led to investor losses.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 03, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Neumora Therapeutics, Inc. ("Neumora" or the "Company") (NASDAQ: NMRA) investors of a class action representing investors who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commencing on or about September 15, 2023. Neumora investors have until April 7, 2025 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint alleges that during the class period, Defendants made materially false or misleading statements and failed to disclose key information. Specifically, Neumora altered BlackThorn’s original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) in an effort to justify proceeding with its Phase Three Program and demonstrate that Navacaprant, its flagship therapeutic candidate, provided statistically significant improvement in treating MDD. Additionally, the company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD. Furthermore, the Phase Two trials lacked sufficient data—particularly regarding patient population size and the male-to-female ratio—making it difficult to accurately predict the outcomes of the KOASTAL-1 study.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

How can Neumora investors recover their losses?

Investors can contact the Portnoy Law Firm for a free case evaluation.

What is the deadline to file a lead plaintiff motion for Neumora?

The deadline to file is April 7, 2025.

What allegations are included in the Neumora lawsuit?

The lawsuit claims Neumora made misleading statements and altered trial criteria.

Who should Neumora investors contact for legal advice?

Investors can reach attorney Lesley F. Portnoy at 310-692-8883 or via email.

What is the focus of the Phase Two trials mentioned?

The trials targeted patients with moderate to severe Major Depressive Disorder.

Last updated: Apr 3, 2025